478 related articles for article (PubMed ID: 31718534)
1. The effect of pneumococcal immunization on total and antigen-specific B cells in patients with severe chronic kidney disease.
Gaultier GN; McCready W; Ulanova M
BMC Immunol; 2019 Nov; 20(1):41. PubMed ID: 31718534
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naïve and previously immunized adult patients with severe chronic kidney disease.
Ulanova M; Huska B; Desbiens A; Gaultier GN; Domonkos V; McCready WG
Vaccine; 2021 Jan; 39(4):699-710. PubMed ID: 33358702
[TBL] [Abstract][Full Text] [Related]
3. Opsonophagocytic activity against Streptococcus pneumoniae in Indigenous and non-Indigenous patients with severe chronic kidney disease immunized with 13-valent pneumococcal conjugate vaccine.
Ulanova M; Huska B; Dubois S; McCready W
Vaccine; 2022 Jul; 40(32):4594-4602. PubMed ID: 35738971
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and Immunological Memory Induced by the 13-Valent Pneumococcal Conjugate Followed by the 23-Valent Polysaccharide Vaccine in HIV-Infected Adults.
Farmaki PF; Chini MC; Mangafas NM; Tzanoudaki MT; Piperi CP; Lazanas MZ; Spoulou VS
J Infect Dis; 2018 Jun; 218(1):26-34. PubMed ID: 29722823
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis.
Vadlamudi NK; Parhar K; Altre Malana KL; Kang A; Marra F
Vaccine; 2019 Feb; 37(8):1021-1029. PubMed ID: 30685252
[TBL] [Abstract][Full Text] [Related]
6. Persistence of antibodies to pneumococcal conjugate vaccine compared to polysaccharide vaccine in patients with Crohn's disease - one year follow up.
Kantsø B; Halkjær SI; Østergaard Thomsen O; Belard E; Gottschalck IB; Jørgensen CS; Krogfelt KA; Slotved HC; Ingels H; Petersen AM
Infect Dis (Lond); 2019 Sep; 51(9):651-658. PubMed ID: 31290715
[No Abstract] [Full Text] [Related]
7. Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients--preliminary report.
Pasiarski M; Rolinski J; Grywalska E; Stelmach-Goldys A; Korona-Glowniak I; Gozdz S; Hus I; Malm A
PLoS One; 2014; 9(12):e114966. PubMed ID: 25506837
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Peterson JT; Stacey HL; MacNair JE; Li J; Hartzel JS; Sterling TM; Benner P; Tamms GM; Musey LK
Hum Vaccin Immunother; 2019; 15(3):540-548. PubMed ID: 30427749
[TBL] [Abstract][Full Text] [Related]
9. Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccination.
van den Biggelaar AHJ; Richmond PC; Fuery A; Anderson D; Opa C; Saleu G; Lai M; Francis JP; Alpers MP; Pomat WS; Lehmann D
PLoS One; 2017; 12(10):e0185877. PubMed ID: 29028802
[TBL] [Abstract][Full Text] [Related]
10. Antigen-specific B-cell response to 13-valent pneumococcal conjugate vaccine in asplenic individuals with β-thalassemia previously immunized with 23-valent pneumococcal polysaccharide vaccine.
Papadatou I; Piperi C; Alexandraki K; Kattamis A; Theodoridou M; Spoulou V
Clin Infect Dis; 2014 Sep; 59(6):862-5. PubMed ID: 24879786
[TBL] [Abstract][Full Text] [Related]
11. Natural immunity against Haemophilus influenzae type a and B-cell subpopulations in adult patients with severe chronic kidney disease.
Gaultier GN; McCready W; Ulanova M
Vaccine; 2019 Jun; 37(28):3677-3684. PubMed ID: 31122854
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease.
Kantsø B; Halkjær SI; Thomsen OØ; Belard E; Gottschalck IB; Jørgensen CS; Krogfelt KA; Slotved HC; Ingels H; Petersen AM
Vaccine; 2015 Oct; 33(41):5464-5469. PubMed ID: 26275480
[TBL] [Abstract][Full Text] [Related]
13. Immune response to pneumococcal conjugate vaccination in asplenic individuals.
Stanford E; Print F; Falconer M; Lamden K; Ghebrehewet S; Phin N; Baxter D; Helbert M; McCann R; Andrews N; Balmer P; Borrow R; Kaczmarski E
Hum Vaccin; 2009 Feb; 5(2):85-91. PubMed ID: 18758242
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying medical conditions.
Jallow S; Madhi SA; Madimabe R; Sipambo N; Violari A; Kala U; Petersen K; Naidoo S; Verwey C; Moore DP; Nunes MC
Vaccine; 2017 Aug; 35(34):4321-4329. PubMed ID: 28688781
[TBL] [Abstract][Full Text] [Related]
15. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
Nuorti JP; Whitney CG;
MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
[TBL] [Abstract][Full Text] [Related]
16. Differential B-cell memory around the 11-month booster in children vaccinated with a 10- or 13-valent pneumococcal conjugate vaccine.
van Westen E; Wijmenga-Monsuur AJ; van Dijken HH; van Gaans-van den Brink JA; Kuipers B; Knol MJ; Berbers GA; Sanders EA; Rots NY; van Els CA
Clin Infect Dis; 2015 Aug; 61(3):342-9. PubMed ID: 25838290
[TBL] [Abstract][Full Text] [Related]
17. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
De Montalembert M; Abboud MR; Fiquet A; Inati A; Lebensburger JD; Kaddah N; Mokhtar G; Piga A; Halasa N; Inusa B; Rees DC; Heath PT; Telfer P; Driscoll C; Al Hajjar S; Tozzi A; Jiang Q; Emini EA; Gruber WC; Gurtman A; Scott DA
Pediatr Blood Cancer; 2015 Aug; 62(8):1427-36. PubMed ID: 25810327
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.
Bhorat AE; Madhi SA; Laudat F; Sundaraiyer V; Gurtman A; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
AIDS; 2015 Jul; 29(11):1345-54. PubMed ID: 25888646
[TBL] [Abstract][Full Text] [Related]
19. Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children.
Sigurdardottir ST; Center KJ; Davidsdottir K; Arason VA; Hjalmarsson B; Elisdottir R; Ingolfsdottir G; Northington R; Scott DA; Jonsdottir I
Vaccine; 2014 Jan; 32(3):417-24. PubMed ID: 24300594
[TBL] [Abstract][Full Text] [Related]
20. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
Svensson T; Kättström M; Hammarlund Y; Roth D; Andersson PO; Svensson M; Nilsson I; Rombo L; Cherif H; Kimby E
Vaccine; 2018 Jun; 36(25):3701-3707. PubMed ID: 29748028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
